A PHASE 1, OPEN-LABEL, 2-PERIOD, FIXED-SEQUENCE STUDY TO INVESTIGATE THE ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION OF [14C]PF-07976016 AND TO ASSESS THE ABSOLUTE BIOAVAILABILITY AND FRACTION ABSORBED OF PF-07976016 IN HEALTHY MALE PARTICIPANTS USING A [14C]-MICROTRACER APPROACH
Latest Information Update: 27 Jun 2025
At a glance
- Drugs PF 07976016 (Primary) ; PF 07976016 (Primary)
- Indications Obesity
- Focus Pharmacokinetics
- Sponsors Pfizer
Most Recent Events
- 22 Jun 2025 Status changed from not yet recruiting to recruiting.
- 17 Jun 2025 New trial record